Sérgio Veloso’s Post

Article No. 133 Title: Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC). Journal: Bioorganic & medicinal chemistry Impact Factor: 3.3 DOI: https://lnkd.in/gRnnwe-S

68Ga-PSMA-11 is a radiopharmaceutical used in positron emission tomography (PET) imaging for detecting prostate cancer. This radiotracer targets prostate-specific membrane antigen (PSMA), a protein that is overexpressed in prostate cancer cells, allowing for highly specific imaging of prostate cancer. When injected into the body, the radioactive gallium-68 emits positrons that generate signals picked up by the PET scanner, providing highly detailed images of the distribution and concentration of PSMA in the body. This imaging helps in the initial staging, restaging, and monitozring of prostate cancer, and it can be useful in guiding treatment decisions. We can mass produce (kg level),process scaling up, pilot supply,raw material supply, and intermediate production. Our production technology is mature and more cost-effective. Feel free to inquire at any time. #68Ga-#PSMA-#11 #detecting #prostate #cancer #radiotracer #targets #prostate-#specific #membrane #antigen https://lnkd.in/gXXKxP2h

When it comes to tumor surface targets for modalities like ADCs, we're always hearing about the usual suspects: HER2, TROP2, Claudin18.2. Using #ASCO24, #AACR24 and BioCentury Inc.'s BCIQ database, we shine a light on emerging targets off that beaten path, and see a trend toward targeting neuronal regulators hijacked by cancer. Were any of these targets on your radar? https://lnkd.in/gwykTWAi

⏰ #SLAS2024 Session Starting: Join us at 12:00 PM EST, as Dr. Cathy Olsen explains how we used patient-derived colorectal cancer organoids to assess differential effects of known anti-cancer compounds on organoid size and morphology using both imaging and a microplate reader-based viability readout. This streamlined readout may be used to guide identification of potential therapeutics early in the screening process, which could then be followed up with more intensive high content imaging or other analyses. We hope to see you there! ➡️ https://bit.ly/3Unmca1   #CancerResearch #3DModels #CellViability #DrugDevelopment #HighContentScreening #TheFutureOfCellCulture #CellXpressAI

Our Co-Founders Dr. Markku Jalkanen and Dr. Sirpa Jalkanen have been nominated as one of three finalists in the prestigious European Inventor Award’s ‘SMEs’ category for 2024, organised by the European Patent Office.   The nomination is in recognition of Markku and Sirpa’s research developing bexmarilimab, Faron’s wholly owned precision cancer immunotherapy candidate. Bexmarilimab is currently being investigated in our ongoing BEXMAB trial, evaluating its safety and efficacy in combination with standard of care in patients with hypomethylating agents (HMAs)-refractory or relapsed #acuteMyeloidLeukemia and #MyelodysplasticSyndromes.   Find out more here: https://lnkd.in/eUKEHJuW   #Award #Faron #bexmarilimab #biotech #drugdevelopment  

1. Dr. Karen Tkach Tuzman of BioCentury Inc. provided an elegant analysis of tumor cell surface targets presented at AACR24 and ASCO24. Among these, five neuronal proteins stood out to me. 2. The five mentioned targets—SEZ6, EPHA5, CNTN4, SLITRK6, and NPTXR—are aberrantly expressed in solid tumors, while in neurons, these targets promote axon and dendrite growth and synapse formation. 3. Dr. Tuzman highlighted a key question for this target class: whether they will exhibit neurotoxicity. She noted that the low blood-brain barrier (BBB) penetration of antibody-based therapies, particularly ADCs, could mitigate this risk. 4. The Destiny-Breast03 study shows that specific ADCs can effectively treat patients with brain metastases. However, since the study primarily enrolled patients with stable metastases post-local treatment, the efficacy in patients with active metastases remains uncertain. 5. The reason for T-Dxd's efficacy in patients with brain metastases is unclear. The integrity of the BBB can change due to pathological conditions like inflammatory diseases (e.g., multiple sclerosis) and primary or secondary brain tumors. However, the blood-tumor barrier (BTB), formed when tumors disrupt BBB integrity, shows highly heterogeneous permeability within tumors and is characterized by active efflux of molecules. 6. The BBB and BTB in patients with brain metastases from primary cancers or brain tumors can be very heterogeneous. Therefore, the neurotoxicity of ADC drugs targeting proteins expressed in neurons warrants careful consideration. Ref: https://lnkd.in/g-UfiDiP

This paper examines the impact of nanomaterials on autophagy, particularly in cancer, highlighting nano-formulations that modulate autophagic pathways for improved drug delivery and therapy, and explores combining these with immunotherapy for enhanced treatment outcomes. You can check it out here: https://lnkd.in/gM4BMRNY #Nanomedicine #Autophagy #CancerResearch #DrugDelivery #Nanotechnology #CellularHomeostasis #CancerTherapy #Immunotherapy #NanoFormulations #BiomedicalEngineering #MolecularBiology #Pharmacology #Oncology #TargetedTherapy #BiotechInnovation

LABN Trending News: FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER https://lnkd.in/gsKeN3mU Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host [...]

I want to share our latest paper titled "Targeted Nano-Delivery of Flutamide with polymeric and lipid nanoparticles" published in the European Polymer Journal. Our comprehensive review delves into the progress and modifications in intelligent delivery methods for Flutamide (FLT), a critical drug for treating androgen-dependent malignancies like prostate cancer and conditions like polycystic ovarian syndrome. The paper opens new possibilities for advanced cancer therapies, emphasizing the transformative potential of NDDS with polymeric nanoparticles. A huge thanks to #Amirhossein_Khanizadeh for his invaluable assistance in this project. #CancerResearch #Nanotechnology #DrugDelivery #PolymericNanoparticles #Flutamide #ProstateCancer #ScientificResearch

As #organoids and #tumoroids become a more popular model in research, there is an increasing need for models, assays, and workflows to study patient-derived samples. In this webinar, Dr. Margarite Matossian presented the Burow Lab translational research project which addressed therapeutics and drug resistance in triple negative breast cancer (#TNBC) using patient-derived organoids in the #pumasystem.     View the full webinar:  https://lnkd.in/dCJpJFN    #3Dcellassay #flowchips #microfluidic #cancerresearch #lifescienceresearch #precisiononcology #3dcellculture #biotech #preclinicalresearch #drugdiscovery #biomarkers #biomarkerdrugdiscovery #cellbasedassay